What is HC Wainwright’s Forecast for CATX FY2025 Earnings?

Perspective Therapeutics, Inc. (NYSE:CATX) – Analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Perspective Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.20) per share for the year, down from their previous forecast of ($1.19). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

A number of other equities research analysts have also recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Finally, Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $14.56.

Perspective Therapeutics Price Performance

CATX stock opened at $2.52 on Friday. The stock’s fifty day simple moving average is $3.03 and its two-hundred day simple moving average is $6.86. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at approximately $34,000. National Bank of Canada FI increased its stake in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC increased its stake in Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics during the 4th quarter valued at approximately $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.